Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Study Identifier
M14-226
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Hepatitis
  • Cirrhosis
  • Renal Impairment
  • Kidney Disease
  • Study Drug
  • ombitasvir/paritaprevir/ritonavir
  • dasabuvir
  • Ribavirin
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 99 Years

    Protocol Summary

    This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24-week regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) \<30, including those on hemodialysis or peritoneal dialysis.

    Study Locations

    No locations found.